Moreover, atherosclerosis (ALS) is a progressive neuromuscular disease caused by the degeneration and impairment of neurons in motor pathways, resulting in muscle function loss and ultimately leading to death within 3 to 5 years.561 Tofersen received its initial approval in the USA for treating ALS in adults with mutations in SOD1 gene. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.